Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Fundamental data now powered by FactSet with hourly updates!

BCRX | Biocryst Pharmaceuticals Inc.

IndexRUT P/E- EPS (ttm)-1.29 Insider Own1.51% Shs Outstand187.91M Perf Week0.12%
Market Cap1.43B Forward P/E- EPS next Y-0.63 Insider Trans-0.83% Shs Float185.31M Perf Month4.13%
Income-242.72M PEG- EPS next Q-0.24 Inst Own92.52% Short Float / Ratio22.29% / 16.29 Perf Quarter7.70%
Sales306.64M P/S4.66 EPS this Y17.29% Inst Trans-1.83% Short Interest41.30M Perf Half Y-11.30%
Book/sh-2.05 P/B- EPS next Y43.14% ROA-46.66% Target Price15.10 Perf Year-40.64%
Cash/sh2.18 P/C3.47 EPS next 5Y22.38% ROE- 52W Range6.62 - 14.50 Perf YTD-34.33%
Dividend- P/FCF- EPS past 5Y-11.25% ROI-55.62% 52W High-48.01% Beta1.85
Dividend %- Quick Ratio5.18 Sales past 5Y181.93% Gross Margin96.87% 52W Low13.89% ATR0.35
Employees531 Current Ratio5.47 Sales Q/Q25.88% Oper. Margin-36.81% RSI (14)57.22 Volatility5.67% 4.31%
OptionableYes Debt/Eq- EPS Q/Q-25.61% Profit Margin-79.15% Rel Volume0.60 Prev Close7.35
ShortableYes LT Debt/Eq- EarningsAug 03 BMO Payout- Avg Volume2.54M Price7.54
Recom1.55 SMA206.08% SMA505.01% SMA200-11.69% Volume761,638 Change2.57%
Date Action Analyst Rating Change Price Target Change
Sep-18-23Upgrade RBC Capital Mkts Sector Perform → Outperform $9 → $10
Aug-04-23Upgrade Jefferies Hold → Buy $11
Jul-13-23Upgrade BofA Securities Neutral → Buy $10
Feb-22-23Upgrade Needham Hold → Buy $14
Nov-02-22Upgrade Evercore ISI In-line → Outperform $14 → $16
Aug-05-22Downgrade Oppenheimer Outperform → Perform
Aug-05-22Downgrade Evercore ISI Outperform → In-line $14
Apr-18-22Downgrade Barclays Overweight → Equal Weight $22 → $13
Apr-11-22Downgrade BofA Securities Buy → Neutral $21 → $14
Dec-10-21Initiated Oppenheimer Outperform $16
Sep-18-23 07:00AM
Sep-05-23 07:00AM
Aug-28-23 08:30AM
Aug-23-23 04:01PM
Aug-04-23 04:56PM
04:01PM Loading…
Aug-03-23 02:30PM
Jul-20-23 09:55AM
Jul-19-23 07:00AM
Jul-18-23 09:42AM
Jul-17-23 07:00AM
09:43AM Loading…
Jul-13-23 09:43AM
Jul-06-23 07:00AM
Jul-03-23 04:23AM
Jun-06-23 07:00AM
Jun-01-23 07:00AM
May-31-23 07:02AM
May-22-23 07:00AM
May-09-23 10:21AM
May-04-23 04:01PM
May-03-23 02:00PM
Apr-27-23 10:03AM
10:02AM Loading…
Apr-26-23 10:02AM
Apr-19-23 07:00AM
Apr-18-23 07:00AM
Apr-17-23 01:24PM
Apr-12-23 07:00AM
Apr-04-23 07:00AM
Mar-31-23 07:00AM
Mar-29-23 04:01PM
Mar-08-23 03:00PM
Mar-02-23 07:00AM
Feb-24-23 07:00AM
Feb-23-23 04:32PM
Feb-22-23 03:29PM
Feb-21-23 11:55AM
Feb-16-23 10:19AM
Feb-15-23 10:00AM
Feb-14-23 10:00AM
Feb-08-23 07:34AM
Feb-07-23 07:00AM
Feb-06-23 07:00AM
Feb-03-23 07:00AM
Jan-26-23 07:00AM
Jan-23-23 07:00AM
Jan-12-23 06:01AM
Jan-09-23 07:05AM
Jan-05-23 07:00AM
Jan-04-23 09:55AM
Dec-16-22 12:10PM
Dec-15-22 02:56PM
Dec-05-22 04:01PM
Nov-30-22 08:03AM
Nov-28-22 07:00AM
Nov-11-22 07:14PM
Nov-10-22 08:00AM
Nov-09-22 07:00AM
Nov-04-22 07:00AM
Nov-03-22 01:30PM
Nov-01-22 10:16PM
Oct-26-22 10:02AM
Oct-25-22 10:01AM
Oct-24-22 07:00AM
Oct-18-22 07:00AM
Oct-10-22 02:51PM
Oct-04-22 07:00AM
Oct-02-22 07:54AM
Sep-20-22 09:16PM
Sep-14-22 04:01PM
Sep-06-22 07:00AM
Sep-01-22 07:27AM
Aug-31-22 04:01PM
Aug-29-22 07:41AM
Aug-26-22 07:00AM
BioCryst Pharmaceuticals, Inc. is a commercial-stage biotechnology company that discovers novel, oral, and small-molecule medicines. The firm focuses on the treatment of rare diseases in which unmet medical needs exist and an enzyme in the biological pathway of the disease. Its programs include BCX9930, an oral Factor D inhibitor for the treatment of complement-mediated diseases, BCX9250, an ALK-2 inhibitor for the treatment of fibrodysplasia ossificans progressiva, and galidesivir, a potential treatment for marburg virus disease and yellow fever. The company was founded in 1986 and is headquartered in Durham, NC.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
SANDERS MACHELLEDirectorJun 15Sale7.984,00031,92025,611Jun 15 04:37 PM
Hutson Nancy JDirectorJun 14Sale8.0412,866103,44381,818Jun 15 04:33 PM
Thackray Helen M.Chief R&D OfficerApr 03Sale8.297,00058,030207,275Apr 05 04:33 PM
Stonehouse Jon PPresident & CEOMar 21Option Exercise3.2231,05599,9971,039,794Mar 23 04:40 PM
Stonehouse Jon PPresident & CEOFeb 01Option Exercise5.45100,000545,0001,108,739Feb 02 05:20 PM
Stonehouse Jon PPresident & CEOFeb 01Sale10.38100,0001,038,0001,008,739Feb 02 05:20 PM
LEE KENNETH B JRDirectorJan 31Option Exercise1.7115,00025,65052,118Feb 02 05:15 PM
Stonehouse Jon PPresident & CEODec 15Sale10.9014,100153,690887,730Dec 19 05:09 PM
Gayer Charles KChief Commercial OfficerDec 15Sale10.906,10066,490211,610Dec 19 04:48 PM
Doyle AnthonyChief Financial OfficerDec 15Sale10.905,70062,130163,966Dec 19 04:55 PM
Barnes Alane PChief Legal OfficerDec 15Sale10.884,17545,424198,770Dec 19 04:38 PM
Thackray Helen M.Chief R&D OfficerDec 15Sale10.893,12534,031133,275Dec 19 04:58 PM
Jones Michael LExec. Director, Finance - PAODec 15Sale10.904454,85010,753Dec 19 04:45 PM
Stonehouse Jon PPresident & CEODec 02Option Exercise1.4282,656117,372984,486Dec 02 06:33 PM
Stonehouse Jon PPresident & CEODec 02Sale12.8082,6561,057,997901,830Dec 02 06:33 PM
Stonehouse Jon PPresident & CEODec 01Option Exercise1.42214,917305,1821,116,747Dec 02 06:33 PM
Jones Michael LExec. Director, Finance - PAODec 01Option Exercise1.428,60012,21219,798Dec 02 06:36 PM
Stonehouse Jon PPresident & CEODec 01Sale13.00214,9172,793,921901,830Dec 02 06:33 PM
Jones Michael LExec. Director, Finance - PAODec 01Sale13.018,600111,88611,198Dec 02 06:36 PM
Babu Yarlagadda SChief Discovery OfficerNov 14Option Exercise1.42100,000142,000330,056Nov 16 04:19 PM
Babu Yarlagadda SChief Discovery OfficerNov 14Sale13.8831,515437,428298,541Nov 16 04:19 PM